Skip to main content
Journal cover image

Accuracy and prognostic significance of oncologists' estimates and scenarios for survival time in a randomised Phase 2 trial of regorafenib in advanced gastric cancer

Publication ,  Conference
Vasista, A; Martin, A; Pavlakis, N; Sjoquist, K; Snow, S; Jonker, D; Chua, YJ; Epstein, R; Bonaventura, A; Khasraw, M; Varma, SC; Singhal, N ...
Published in: ANNALS OF ONCOLOGY
September 1, 2017

Duke Scholars

Published In

ANNALS OF ONCOLOGY

EISSN

1569-8041

ISSN

0923-7534

Publication Date

September 1, 2017

Volume

28

Location

Madrid, SPAIN

Publisher

OXFORD UNIV PRESS

Conference Name

42nd European-Society-for-Medical-Oncology Congress (ESMO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Vasista, A., Martin, A., Pavlakis, N., Sjoquist, K., Snow, S., Jonker, D., … Kiely, B. (2017). Accuracy and prognostic significance of oncologists' estimates and scenarios for survival time in a randomised Phase 2 trial of regorafenib in advanced gastric cancer. In ANNALS OF ONCOLOGY (Vol. 28). Madrid, SPAIN: OXFORD UNIV PRESS.
Vasista, A., A. Martin, N. Pavlakis, K. Sjoquist, S. Snow, D. Jonker, Y. J. Chua, et al. “Accuracy and prognostic significance of oncologists' estimates and scenarios for survival time in a randomised Phase 2 trial of regorafenib in advanced gastric cancer.” In ANNALS OF ONCOLOGY, Vol. 28. OXFORD UNIV PRESS, 2017.
Vasista A, Martin A, Pavlakis N, Sjoquist K, Snow S, Jonker D, et al. Accuracy and prognostic significance of oncologists' estimates and scenarios for survival time in a randomised Phase 2 trial of regorafenib in advanced gastric cancer. In: ANNALS OF ONCOLOGY. OXFORD UNIV PRESS; 2017.
Vasista A, Martin A, Pavlakis N, Sjoquist K, Snow S, Jonker D, Chua YJ, Epstein R, Bonaventura A, Khasraw M, Varma SC, Singhal N, Ransom DT, Aubin F, Burkes R, Lim H, Lemay F, Begbie S, Stockler MR, Kiely B. Accuracy and prognostic significance of oncologists' estimates and scenarios for survival time in a randomised Phase 2 trial of regorafenib in advanced gastric cancer. ANNALS OF ONCOLOGY. OXFORD UNIV PRESS; 2017.
Journal cover image

Published In

ANNALS OF ONCOLOGY

EISSN

1569-8041

ISSN

0923-7534

Publication Date

September 1, 2017

Volume

28

Location

Madrid, SPAIN

Publisher

OXFORD UNIV PRESS

Conference Name

42nd European-Society-for-Medical-Oncology Congress (ESMO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 1112 Oncology and Carcinogenesis